Section Arrow
Quote
LKFT.NASDAQ
- Lakefront Biotherapeutics
Quotes are at least 15-min delayed:2026/05/08 11:49 EDT
Regular Hours
Last
 27.76
+0.03 (+0.11%)
Day High 
29.7 
Prev. Close
27.73 
1-M High
-- 
Volume 
25.77K 
Bid
27.46
Ask
28.01
Day Low
27.685 
Open
29.35 
1-M Low
-- 
Market Cap 
1.83B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.87/0.24
Enterprise Value
1.83B
Balance Sheet
Book Value Per Share
57.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.11B
Operating Revenue Per Share
8.74
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TRAWTraws Pharma Inc1.995+0.295+17.35%2.07PE
MRNAModerna54.49+5.95+12.26%-- 
NVAXNovavax10.395+1.165+12.62%3.63PE
ENGNenGene Therapeutics Inc1.64-0.08-4.65%-- 
IOVAIovance Biotherapeutics3.4-0.15-4.23%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.